FAP and central nervous system cancer: Although it failed in clinical trials more than two decades ago and has since been marginalized as an anti-FAP mAb by other novel agents [6,15], we chose this mAb because it is commercially available, could be produced in large quantities using hybridoma technology and allowed us to probe FAP expression on glioma cells in a facile manner.